LIFECORE BIOMEDICAL, INC. \DE\
Financial highlights
| Metric | FY 05/25/25 | FY 05/26/24 | FY 05/28/23 | FY 02/26/23 | FY 11/27/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $128.9M | $128.3M | $103.3M | — | — |
| Cost of revenue | $88.6M | $86.4M | $75.3M | — | — |
| Gross profit | $40.3M | $41.9M | $28.0M | — | — |
| Selling, general & administrative | $44.0M | $40.5M | $39.0M | — | — |
| Research and development | $8.3M | $8.6M | $8.7M | — | — |
| Operating expenses | — | $50.7M | $49.8M | — | — |
| Operating income | -$17.2M | -$8.8M | -$21.8M | — | — |
| Interest expense | — | — | $17.6M | — | — |
| Pretax income | -$38.7M | $9.5M | -$63.9M | — | — |
| Income tax expense | $43,000 | $183,000 | $308,000 | — | — |
| Net income | -$38.7M | $12.0M | -$99.6M | — | — |
| Balance Sheet | |||||
| Cash and equivalents | $8.3M | $8.5M | $19.1M | $3.0M | $5.9M |
| Current assets | $85.7M | $81.0M | $93.9M | $83.1M | $119.1M |
| Total assets | $239.3M | $254.0M | $253.5M | $236.7M | $276.0M |
| Current liabilities | $30.2M | $38.9M | $39.3M | $37.4M | $195.6M |
| Total liabilities | $191.9M | $200.1M | $218.5M | $163.1M | $204.8M |
| Total debt | $188.3M | $187.5M | $150.2M | — | — |
| Stockholders' equity | $1.3M | $11.3M | -$4.2M | $35.0M | $71.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$206,000 | $257,000 | -$17.4M | — | — |
| Depreciation and amortization | $8.0M | $8.0M | $13.2M | — | — |
| Stock-based compensation | $10.2M | $6.2M | $3.6M | — | — |
| Capital expenditure | $13.4M | $18.4M | $6.9M | — | — |
| Free cash flow | -$13.6M | -$18.1M | -$24.4M | — | — |
| Share repurchases | $490,000 | — | — | — | — |
Shares outstanding 37.5M · Free float 6.7%
Annual filing data through FY ended May 25, 2025; float as of July 11, 2026.